According to Mara Goldstein, the biotech industry is in "voracious" need for funding. She says the sector has not seen a tremendous amount of funding in years, which could change if M&A activity increases under a new administration. Mara discusses the "blockbuster" drugs will shake up the industry and biotech's "A.I. equivalents".